NTRB Stock Analysis
NT
Uncovered
Nutriband Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida and currently employs 13 full-time employees. The company went IPO on 2017-06-20. The firm's lead product is its AVERSA technology, an abuse deterrent technology that can be incorporated into any transdermal patch to deter the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. Its first product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an existing generic fentanyl patch with its AVERSA technology to reduce the abuse and misuse of fentanyl patches. The company is also focused on the development of additional products utilizing the AVERSA abuse deterrent transdermal technology, which include AVERSA Buprenorphine and AVERSA Methylphenidate. In addition, it is developing a portfolio of transdermal pharmaceutical products to deliver commercially available drugs or biologics that are typically delivered by injection. Its subsidiaries include 4P Therapeutics LLC and Pocono Pharmaceuticals Inc.